The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program

By sjmartinez • April 27, 2025

Hanauer SB, Torres EA, Aragon-Han P, Chapman JC, Swaminath AC, Arai R, Butnariu M, Lee TC, Rabizadeh S, Check M, Barrett TA, Hashash JG, Meister T, Yen EF, Kinnucan J, Stein DJ, Ziring D, Shaposhnikov R, Sinh P, Qazi TM, Yarur AJ, Monzur F, Dervieux T, Abraham BP. The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program. Pharmaceutics. 2025 Mar 27;17(4):428. doi: 10.3390/pharmaceutics17040428. PMID: 40284422; PMCID: PMC12030419.

Tags: adalimumab, Cedars Sinai DoM, clearance, Digestive Diseases, dose optimization, inflammatory bowel disease, pharmacokinetics; precision medicine, precision-guided dosing, Publications, real-world data, therapeutic drug monitoring

Related Posts

Association of Eicosanoids and Eicosanoid-Related Metabolites With Obesity and Cardiometabolic Traits

Chitsazan M, Parekh JK, Grundmann AL, Lau ES, Alotaibi M, Yu B, Rebholz CM, Selvin E, Allen NB, Allison MA, Jain M, Cheng S, Ho[...]

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial

Baden LR, Shah NS, Liu STH, Cohen J, Moy J, Kumar A, McComsey GA, Chen P, Floris-Moore M, Singer NG, Fernandez I, Slandzicki AJ, Wiley[...]

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S,[...]